It’s “arguably the most intense battleground stock the biotech oncology sector has ever witnessed,” declares the author of today’s article in regards to the stock he proceeds to examine – one which has a passionate group betting on it on one side and an equally passionate group betting against it (and calling it “One of the biggest scams of the 21st century”) on the other. So, with critical phase 3 clinical trial results for its only prominent drug candidate set to be released in May, what’s causing so much controversy for this stock, and who’s right – the bears or the bulls? CLICK HERE.
The Bears vs. The Bulls On “The Hottest Battleground Stock In Cancer Treatment”
- by Bob Mitchell